



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

Intravesical mitoMYcin-C (Maintenance)



* M T O M - 0 0 0 0 - 0 4 - 1 2 - G U *



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Low risk non-muscle-invasive urinary bladder transitional cell carcinoma.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC \geq 1000; HB \geq 80; Plt \geq 100,000

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
mitoMYcin-C	40 mg	IV in 20 - 40 mL NS intravesical.	D1
Maintenance: to be repeated every month for 12 months, starting 6 weeks after completion of induction.			

Special instructions: Minimise oral fluids (especially those containing caffeine) for 6 - 8 hours before each treatment to minimise dilution of drug in the bladder.

Treatment Description:

Cycle	Date	mitoMYcin-C	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for \geq 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No